Click here to close now.

Welcome!

News Feed Item

COPD Drug Market Opportunity and Clinical Pipeline Analysis

DALLAS, April 19, 2014 /PRNewswire/ --


ReportsnReports.com offers COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014 to 2018 industry research report in its store at http://www.reportsnreports.com/reports/280894-copd-drug-market-opportunity-clinical-pipeline-analysis.html .

The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Some of the drugs which are major contributors to this growth include once-daily LABA/LAMA fixed-dose combinations such as QVA-149, umeclidinium bromide/vilanterol and olodaterol/tiotropium. By 2018, it is expected that the combinations of LABA/LAMA would the leading drugs driving sales in the COPD therapy market and by 2021, these drugs would account for more than 25% of the market share. While in 2013, close to 50% of the global market was accounted by the US, with the other regions together accounting for 50%. However, it is expected that by 2018, the share of the USA would reduce marginally to 45%, while the lost share of this region would be taken over by the Asian region.

Companies discussed in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include Almirall, AstraZeneca, Boehringer Ingelheim, Bayer, Chiesi Farmaceutici, Forest Laboratories, Lallemand Pharma, Merck & Co, Novartis and Sunovion Pharmaceuticals. Order  a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=280894 .

Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide.

Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler.

ThisCOPD Drug Market Opportunity & Clinical Pipeline Analysis  Report Highlights:

• COPD Drug Market Overview
• COPD Patient Base: Global, US & Europe
• FDA & EMA Guidelines on Clinical Investigation of COPD Drugs
• COPD Drug Clinical Pipeline by Phase & Country
• COPD Drug in Development Phase: 174
• Majority of COPD Drugs in Preclinical Phase: 72
• Marketed COPD Drugs: 36
• Discontinued & Suspended COPD Drug Profiles

Other newly published reports on the pharmaceuticals industry available with us:

China Pharmaceutical Distribution Industry Report, 2013 market research says thanks to the continuous advancement in new medical reform, China's pharmaceutical distribution industry has maintained a fairly rapid growth in recent years, with the sales value showed a CAGR of roughly 20% in 2005-2013. Companies discussed in this report include China National Accord Medicines, Nanjing Pharmaceutical Co., Ltd (NPC), Chongqing Tongjunge, Shanghai No.1 Pharmacy, China National Medicines, Huadong Medicine, Cachet, Jointown, Realcan Pharmaceutical¸ Shanghai Pharma, Zhejiang Int'l Group, Zhejiang Zhenyuan and CNPIC. Complete report is available at http://www.reportsnreports.com/reports/280794-china-pharmaceutical-distribution-industry-report-2013.html .

Market Research Report on Global and Chinese Benzarone Industry, 2009-2019 is a professional and in-depth market survey on global and Chinese benzarone markets.  This report provides forecasts information on 2014-2019 Global and China Capacity, Production, and Production Value of Benzarone, 2014-2019 Benzarone Industry Cost and Profit Estimation, 2014-2019 Global and China Market Share of Benzarone, 2014-2019 Global and China Supply and Consumption of Benzarone and 2014-2019 China Import and Export of Benzarone. Complete report is available at http://www.reportsnreports.com/reports/280193-market-research-report-on-global-and-chinese-benzarone-industry-2009-2019.html .

List of Figures provided in COPD Drug Market Opportunity & Clinical Pipeline Analysis research report include:

Figure 1-1: Global - People Suffering With COPD (Million), 2013-2018

Figure 1-2: US - People Suffering With COPD (Million), 2013-2018

Figure 1-3: US - People Suffering With COPD by Age Group (%)

Figure 1-4: Europe - People Suffering With COPD (Million), 2013-2018

Figure 1-5: Europe - Death from COPD ('000) , 2005 & 2030

Figure 1-6: Global COPD Drug Market (US$ Billion), 2012-2018

Figure 1-7: Number of COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-8: COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-9: Number of Discontinued COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-10: Discontinued COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-11: Number of Suspended COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-12: Suspended COPD Drugs in Clinical Trial by Phase (%), 2014

Figure 1-13: Number of No Development in COPD Drugs in Clinical Trial by Phase, 2014

Figure 1-14: No Development in COPD Drugs in Clinical Trial by Phase (%), 2014

About Us: 

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact: 

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

http://www.deepresearchreports.com/cat/pharmaceuticals-market-research.html

Connect With Us on: 

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/


SOURCE ReportsnReports.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Overgrown applications have given way to modular applications, driven by the need to break larger problems into smaller problems. Similarly large monolithic development processes have been forced to be broken into smaller agile development cycles. Looking at trends in software development, microservices architectures meet the same demands. Additional benefits of microservices architectures are compartmentalization and a limited impact of service failure versus a complete software malfunction. ...
"We help to transform an organization and their operations and make them more efficient, more agile, and more nimble to move into the cloud or to move between cloud providers and create an agnostic tool set," noted Jeremy Steinert, DevOps Services Practice Lead at WSM International, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
The basic integration architecture, as defined by ESBs, hasn’t changed for more than a decade. Most cloud integration providers still rely on an ESB architecture and their proprietary connectors. As a result, enterprise integration projects suffer from constraints of availability and reliability of these connectors that are not re-usable across other integration vendors. However, the rapid adoption of APIs and almost ubiquitous availability of APIs amongst most SaaS and Cloud applications are ra...
Agile, which started in the development organization, has gradually expanded into other areas downstream - namely IT and Operations. Teams – then teams of teams – have streamlined processes, improved feedback loops and driven a much faster pace into IT departments which have had profound effects on the entire organization. In his session at DevOps Summit, Anders Wallgren, Chief Technology Officer of Electric Cloud, will discuss how DevOps and Continuous Delivery have emerged to help connect dev...
"What Dyn is able to do with our Internet performance and our Internet intelligence is give companies visibility into what is actually going on in that cloud," noted Corey Hamilton, Product Marketing Manager at Dyn, in this SYS-CON.tv interview at 16th Cloud Expo, held June 9-11, 2015, at the Javits Center in New York City.
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists addressed this very serious issue of pro...
Internet of Things is moving from being a hype to a reality. Experts estimate that internet connected cars will grow to 152 million, while over 100 million internet connected wireless light bulbs and lamps will be operational by 2020. These and many other intriguing statistics highlight the importance of Internet powered devices and how market penetration is going to multiply many times over in the next few years.
Manufacturing has widely adopted standardized and automated processes to create designs, build them, and maintain them through their life cycle. However, many modern manufacturing systems go beyond mechanized workflows to introduce empowered workers, flexible collaboration, and rapid iteration. Such behaviors also characterize open source software development and are at the heart of DevOps culture, processes, and tooling.
Today air travel is a minefield of delays, hassles and customer disappointment. Airlines struggle to revitalize the experience. GE and M2Mi will demonstrate practical examples of how IoT solutions are helping airlines bring back personalization, reduce trip time and improve reliability. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Dr. Sarah Cooper, M2Mi’s VP Business Development and Engineering, will explore the IoT cloud-based platform technologies drivi...
Containers have changed the mind of IT in DevOps. They enable developers to work with dev, test, stage and production environments identically. Containers provide the right abstraction for microservices and many cloud platforms have integrated them into deployment pipelines. DevOps and Containers together help companies to achieve their business goals faster and more effectively. In his session at DevOps Summit, Ruslan Synytsky, CEO and Co-founder of Jelastic, reviewed the current landscape of...
Live Webinar with 451 Research Analyst Peter Christy. Join us on Wednesday July 22, 2015, at 10 am PT / 1 pm ET In a world where users are on the Internet and the applications are in the cloud, how do you maintain your historic SLA with your users? Peter Christy, Research Director, Networks at 451 Research, will discuss this new network paradigm, one in which there is no LAN and no WAN, and discuss what users and network administrators gain and give up when migrating to the agile world of clo...
SYS-CON Events announced today that JFrog, maker of Artifactory, the popular Binary Repository Manager, will exhibit at SYS-CON's @DevOpsSummit Silicon Valley, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. Based in California, Israel and France, founded by longtime field-experts, JFrog, creator of Artifactory and Bintray, has provided the market with the first Binary Repository solution and a software distribution social platform.
"We got started as search consultants. On the services side of the business we have help organizations save time and save money when they hit issues that everyone more or less hits when their data grows," noted Otis Gospodnetić, Founder of Sematext, in this SYS-CON.tv interview at @DevOpsSummit, held June 9-11, 2015, at the Javits Center in New York City.
Internet of Things (IoT) will be a hybrid ecosystem of diverse devices and sensors collaborating with operational and enterprise systems to create the next big application. In their session at @ThingsExpo, Bramh Gupta, founder and CEO of robomq.io, and Fred Yatzeck, principal architect leading product development at robomq.io, discussed how choosing the right middleware and integration strategy from the get-go will enable IoT solution developers to adapt and grow with the industry, while at th...
Containers are revolutionizing the way we deploy and maintain our infrastructures, but monitoring and troubleshooting in a containerized environment can still be painful and impractical. Understanding even basic resource usage is difficult – let alone tracking network connections or malicious activity. In his session at DevOps Summit, Gianluca Borello, Sr. Software Engineer at Sysdig, will cover the current state of the art for container monitoring and visibility, including pros / cons and liv...